FINNENCE ▪ THE WIRE FILE
THE WIRE · № 57255
Company■ Unclear/unknown
Phase 3 results posted: Study of PK and Safety of the LicartTM Topical System in Pediatric and Adult Participants With Minor Soft Tissue Injury — IBSA Institut Biochimique SA
KINDCompany
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-09-30 12:00 UTC
LAST UPDATE2026-09-30 12:00 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
IBSA posts Phase 3 PK and safety results for a topical diclofenac system; no efficacy conclusions are provided.
Trial completion, no listed exposure
CATALYST TO WATCH
Publication or approval filing
MAIN RISK
Private sponsor, no ticker
FULL DISPATCH
Sponsor: IBSA Institut Biochimique SA; Status: Completed; Conditions: Soft Tissue Injuries; Interventions: Licart™ (diclofenac epolamine) topical system; Enrollment: 151 (actual); First posted: 2021-12-29; Results posted: 2026-09-30; NCT: NCT05171673
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Phase 3 results posted: Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy — Teva Pharmaceuticals USA2026-09-30 12:00 UTC
Phase 3 results posted: Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy — Teva Pharmaceuticals USA2026-09-30 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases — Takeda2026-09-30 12:00 UTC
Phase 3 results posted: A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases — Takeda2026-09-30 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis2026-09-30 12:03 UTC
New Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis2026-09-30 12:03 UTC
→CORRELATIONshares Healthcare
HealthPartners and Essentia Health Propose Major Merger2026-09-30 12:56 UTC
HealthPartners and Essentia Health Propose Major Merger2026-09-30 12:56 UTC
→CORRELATIONshares Healthcare
Masimo Wins Two OCTANE High Tech Awards - Company Recognized for 'Deal of the Year' and 'Best Technology Leadership Team'2026-09-30 13:05 UTC
Masimo Wins Two OCTANE High Tech Awards - Company Recognized for 'Deal of the Year' and 'Best Technology Leadership Team'2026-09-30 13:05 UTC
←CORRELATIONshares Healthcare
Union, governor’s office strike deal on state employee healthcare costs2026-09-29 22:54 UTC
Union, governor’s office strike deal on state employee healthcare costs2026-09-29 22:54 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.